Oobli, a global sweet protein platform, continues to expand its sweet protein offerings, having just received another “no questions” letter from the U.S. Food & Drug Administration (FDA). With GRAS approval, the FDA has confirmed that Oobli’s protein-based sweetener monellin, a novel sweet protein, is safe to be used as a sweetener in food and beverages. Oobli is the first company in the world to successfully build a platform of multiple sweet proteins, providing the versatility to easily integrate with and help rehabilitate any sweet food or beverage. Monellin joins Oobli’s no-questions letter for brazzein that was received by the FDA earlier this year. In addition, the company has added Heather Malenshek and Geoffrey Duyk MD, PhD to its board of directors, expanding its tech leadership and commercial expertise.
Food companies and R&D teams around the globe—including Grupo Bimbo, one of the largest CPG companies in the world, along with a growing number of Oobli protein-sweetened partner products coming in 2025—are working closely with Oobli to integrate sweet proteins into their product formulations. Plant-based sweet proteins are a cost-effective sweetener option that have the potential to replace more than 70% of sugar in the majority of food and beverages like sodas, baked goods, candies and more. Sweet proteins can also be used to replace or complement other natural sweeteners.